Glenn Merlino
Overview
Explore the profile of Glenn Merlino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
5347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pagadala M, Sears T, Wu V, Perez-Guijarro E, Kim H, Castro A, et al.
Nat Commun
. 2023 May;
14(1):2744.
PMID: 37173324
With the continued promise of immunotherapy for treating cancer, understanding how host genetics contributes to the tumor immune microenvironment (TIME) is essential to tailoring cancer screening and treatment strategies. Here,...
12.
Yu Y, Dai M, Huang L, Chen W, Yu E, Mendoza A, et al.
iScience
. 2023 Feb;
26(2):106070.
PMID: 36824269
encodes a tumor suppressor with lipid and protein phosphatase activities whose dysfunction has been implicated in melanomagenesis; less is known about how its phosphatases regulate melanoma metastasis. We demonstrate that...
13.
Marie K, Merlino G, Day C
Dev Cell
. 2022 Nov;
57(21):2447-2449.
PMID: 36347238
Melanoma evolution may recapitulate the embryonic development of its progenitor tissue, neural crest (NC), but the exact process is unclear. In a recent issue of Nature, Karras et al. (2022)...
14.
Liu A, Zhu Y, Chen W, Merlino G, Yu Y
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954330
PTEN is the second most highly mutated tumor suppressor in cancer, following only p53. The PTEN protein functions as a phosphatase with lipid- and protein-phosphatase activity. PTEN-lipid-phosphatase activity dephosphorylates PIP3...
15.
Zhang Y, Vu T, Palmer D, Kishton R, Gong L, Huang J, et al.
Nat Med
. 2022 Aug;
28(10):2219.
PMID: 35953723
No abstract available.
16.
Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins M, Boire A, et al.
Pigment Cell Melanoma Res
. 2022 Aug;
35(6):554-572.
PMID: 35912544
Brain metastases are the most common brain malignancy. This review discusses the studies presented at the third annual meeting of the Melanoma Research Foundation in the context of other recent...
17.
Grafanaki K, Merlino G, Day C
Trends Cancer
. 2022 Jun;
8(8):626-628.
PMID: 35718707
Patients with congenital giant nevi (CGN), which can compromise quality of life and progress to melanoma, have limited treatment options. Choi et al. have demonstrated that topical application of a...
18.
Zhang Y, Vu T, Palmer D, Kishton R, Gong L, Huang J, et al.
Nat Med
. 2022 May;
28(7):1421-1431.
PMID: 35501486
Despite breakthroughs in cancer immunotherapy, most tumor-reactive T cells cannot persist in solid tumors due to an immunosuppressive environment. We developed Tres (tumor-resilient T cell), a computational model utilizing single-cell...
19.
Li D, English H, Hong J, Liang T, Merlino G, Day C, et al.
Mol Ther Oncolytics
. 2022 Mar;
24:849-863.
PMID: 35317524
Chimeric antigen receptor (CAR)-T cell therapy shows excellent potency against hematological malignancies, but it remains challenging to treat solid tumors, mainly because of a lack of appropriate antigenic targets and...
20.
Day C, Perez-Guijarro E, Lopes A, Goldszmid R, Murgai M, Wakefield L, et al.
Cancer Cell
. 2022 Feb;
40(3):231-232.
PMID: 35180384
No abstract available.